This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cowen, P.J. Articles by Sargent, P.A. Search for Related Content PubMed PubMed Citation Articles by Cowen, P.J. Articles by Sargent, P.A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission

University Department of Psychiatry, Littlemore Hospital, Oxford OX4 4XN, UK.

P.A. Sargent

University Department of Psychiatry, Littlemore Hospital, Oxford OX4 4XN, UK.

We studied the effect of the selective serotonin reuptake inhibitor (SSRI), paroxetine, on basal plasma prolactin concentrations in 11 healthy subjects. Subjects were tested before paroxetine, and after 1 and 3 weeks of treatment (20 mg daily). On each test occasion prolactin levels were sampled before and following administration of a placebo capsule, for a total of 4 h. After 3 weeks paroxetine treatment plasma prolactin levels were significantly higher than those seen either pre-treatment or after 1 week of treatment. In contrast, 1 week of paroxetine treatment did not significantly increase prolactin concentrations over pre-treatment values. Plasma concentrations of paroxetine did not differ between 1 and 3 weeks of treatment. The secretion of plasma prolactin is, in part, under the tonic regulation of serotonergic pathways and the present results therefore support animal experimental data suggesting that SSRIs produce a delayed increase in some aspects of brain serotonin neurotransmission.

Key Words: paroxetine • prolactin • serotonin • SSRI

Journal of Psychopharmacology, Vol. 11, No. 4, 345-348 (1997)
DOI: 10.1177/026988119701100410


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. E. Molitch Medication-Induced Hyperprolactinemia Mayo Clin. Proc., August 1, 2005; 80(8): 1050 - 1057. [Abstract] [PDF]

				A. T Strachan, J. B Leiper, and R. J Maughan Paroxetine administration to influence human exercise capacity, perceived effort or hormone responses during prolonged exercise in a warm environment Exp Physiol, November 1, 2004; 89(6): 657 - 664. [Abstract] [Full Text] [PDF]

				J. A. J. Schmitt, M. J. Kruizinga, and W. J. Riedel Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors J Psychopharmacol, May 1, 2001; 15(3): 173 - 179. [Abstract] [PDF]

				B. J. Goldstein and P. J Goodnick Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics J Psychopharmacol, January 1, 1998; 12(4_suppl): 55 - S87. [Abstract] [PDF]